Enzo Diagnostics has been awarded US Patent No. 8,445,664, "Kits for amplifying and detecting nucleic acid sequences."
Elazar Rabbani, Jannis Stavrianopoulos, James Donegan, Jack Coleman, and Marleen Walter are named as inventors.
Provides novel processes for amplifying nucleic acid sequences of interest, including linear and non-linear amplification. In linear amplification, a single initial primer or nucleic acid construct is used to carry out the amplification process. In non-linear amplification, a first initial primer or nucleic acid construct is employed with a subsequent initial primer or nucleic acid construct. The patent also provides other non-linear amplification processes in which a first initial primer or nucleic acid construct is deployed with a second initial primer or nucleic acid construct to amplify the specific nucleic acid sequence of interest and its complement. A singular primer or a singular nucleic acid construct capable of non-linear amplification can also be used to carry out non-linear amplification. The patent also discloses a post-termination labeling process for nucleic acid sequencing that is based upon the detection of tagged molecules that are covalently bound to chemically reactive groups provided for chain terminators. The patent also describes a process for producing nucleic acid sequences having decreased thermodynamic stability to complementary sequences; and unique nucleic acid polymers, kits, and the like.
Applied Biosystems (Life Technologies) has been awarded US Patent No. 8,445,657, "Multiplex compositions and methods for quantification of human nuclear DNA and human male DNA and detection of PCR inhibitors."
Jaiprakash Shewale, Manohar Furtado, Pius Brzoska, Maura Barbisin, Rixun Fang, Michael Malicdem, and Cristin O'Shea are named as inventors.
Relates to a method for simultaneous quantification of human nuclear DNA and human male DNA in a biological sample while also detecting the presence of PCR inhibitors in a single reaction. The multiplex quantification method also provides a ratio of human nuclear and male DNA present in a biological sample. Such sample characterization is useful for achieving efficient and accurate results in downstream molecular techniques such as genotyping, the patent's abstract states.
Life Technologies has been awarded US Patent No. 8,445,209, "Nucleic acid compositions and nucleic acid amplification-based methods for detecting E. coli O157:H7."
Paolo Vatta, Olga Petrauskene, Manohar Furtado, Pius Brzoska, Lily Wong, Melissa Barker, and Craig Cummings are named as inventors.
Discloses primer and probe compositions, PCR assays, methods, and kits for the specific detection of Escherichia coli O157:H7 and not E. coli O55:H7 from a variety of samples. In some embodiments, the methods comprise: hybridizing at least a first pair of polynucleotide primers to at least a first target polynucleotide sequence; hybridizing at least a second pair of polynucleotide primers to at least a second target polynucleotide sequence; amplifying the target polynucleotide sequences; and detecting the amplified target polynucleotide sequence products, wherein the detection of both the first and second amplified target polynucleotide sequence products is indicative of the presence of E. coli O157:H7 in a sample and not E. coli O55:H7.
Roche Molecular Systems has been awarded US Patent No. 8,445,204, "Methods of identification of methylation of CpG."
Russell Higuchi is named as the inventor.
Relates to materials and methods for the identification of methylated nucleotides in samples of genomic DNA. The invention also relates to methods of diagnosis of specific conditions by identification of specific methylated nucleotides.
Olympus and the National University Corporation of the Hamamatsu University School of Medicine, both in Japan, have been awarded US Patent No. 8,445,202, "Method of detecting colon cancer marker."
Shigeru Kanaoka is named as the inventor.
The patent intends to provide a non-invasive and convenient method superior in sensitivity and specificity to the existing fecal occult blood test for detecting a tumor marker to diagnose colon cancer. More specifically, the method comprises collecting a biological sample that is immediately frozen using liquid nitrogen in some cases; homogenizing the sample in the presence of an inhibitor of an RNA-digesting enzyme to give a suspension; extracting RNA from the obtained suspension; subjecting the extracted RNA to reverse transcription to give cDNA; amplifying the obtained cDNA; and then detecting the amplified cDNA. This method is characterized by no need to separate cell components from the biological sample.
Instituto de Salud Carlos III of Madrid has been awarded US Patent No. 8,445,195, "Method and kit for the detection of bacterial species by means of DNA analysis."
Pedro Fernandez, Raquel Nieto, Isabel Garcia, Isabel Moreno, and Maria Jimenez Alonso are named as inventors.
Relates to the detection and identification of different bacterial species, all of which cause zoonosis, based on DNA analysis. More specifically, the invention provides the primers, probes, genes, and genic regions required to apply a method to simultaneously detect bacteria and bacterial groups belonging to the genera Anaplasma, Ehrlichia, Borrelia, Bartonella, Coxiella, Rickettsia, and Francisella based on multiple PCR analyses by reverse line blotting, as well as a kit to carry out said analyses.